ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Asymmetric Cu─N─Ru Bridgedsite Nanozyme-Loaded Injectable Thermogel Boosts Cuproptosis-Like Death for Multidrug-Resistant Urinary Tract Infections.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Multidrug-resistant urinary tract infections (MDR-UTIs) remain one of the most challenging clinical infections globally owing to the paucity of effective therapeutic agents. Nanozymes-triggered cuproptosis-like bacterial death has emerged as a promising bactericidal strategy. However, its efficacy is compromised by insufficient catalytic sites and suboptimal synergy among active centers. Consequently, the development of nanozymes capable of efficiently inducing cuproptosis-like death holds considerable potential for treating MDR-UTIs. Herein, the Cu-ZIF8-Ru nanozyme was engineered that leverages an asymmetric heterobimetallic Cu─N─Ru bridged catalytic center to achieve efficient multienzyme activities and trigger cuproptosis-like death in MDR-UTIs. Theoretical simulations revealed that introducing Ru sites as secondary catalytic centers upshifts the Cu d-band center, thereby lowering activation barriers and enhancing catalytic activity at the Cu─N─Ru active site. Cu-ZIF8-Ru nanozyme demonstrated strong bactericidal effects against MDR-bacteria by promoting intracellular Cu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.